Neil Davie
- Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT-1 studyBy Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marc Humbert, Zhi-Cheng Jing, Anne M. Keogh, David Langleben, Lewis J. Rubin, Michael Ochan Kilama, Arno Fritsch, Neil Davie and Hossein-Ardeschir GhofraniNazzareno Galiè1Institute of Cardiology, University of Bologna, Bologna, ItalyFriedrich Grimminger2Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center of Lung Research (DZL), Giessen, GermanyEkkehard Grünig3Centre for Pulmonary Hypertension at Thoraxclinic Heidelberg, Thoraxclinic at the University Hospital Heidelberg, Heidelberg, GermanyMarc Humbert4Univ. Paris-Sud; Inserm U999; AP-HP, Hôpital Bicêtre, Service De Pneumologie, Le Kremlin-Bicêtre, FranceZhi-Cheng Jing5Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, ChinaAnne M. Keogh6Heart Lung Transplant Unit, St Vincent's Hospital, Sydney, AustraliaDavid Langleben7Center for Pulmonary Vascular Disease, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, CanadaLewis J. Rubin8School of Medicine, University of California, San Diego, La Jolla, United StatesMichael Ochan Kilama9Global Clinical Development, Bayer HealthCare Pharmaceuticals, Milan, ItalyArno Fritsch10Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyNeil Davie10Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyHossein-Ardeschir Ghofrani2Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center of Lung Research (DZL), Giessen, Germany
- Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 studyBy Ekkehard Grünig, Nazzareno Galiè, Marc Humbert, Anne M. Keogh, David Langleben, Lewis J. Rubin, Rudolf Speich, Arno Fritsch, Neil Davie and Hossein-Ardeschir GhofraniEkkehard Grünig1Centre for Pulmonary Hypertension at Thoraxclinic Heidelberg, Thoraxclinic at the University Hospital Heidelberg, Heidelberg, GermanyNazzareno Galiè2Institute of Cardiology, University of Bologna, Bologna, ItalyMarc Humbert3Univ. Paris-Sud; Inserm U999; AP-HP, Hôpital Bicêtre, Service De Pneumologie, Le Kremlin-Bicêtre, FranceAnne M. Keogh4Heart Lung Transplant Unit, St Vincent's Hospital, Sydney, AustraliaDavid Langleben5Center for Pulmonary Vascular Disease, Lady Davis Institute For Medical Research, Jewish General Hospital, McGill University, Montreal, CanadaLewis J. Rubin6School of Medicine, University of California, San Diego, La Jolla, United StatesRudolf Speich7Department of Internal Medicine, University Hospital Zurich, Zurich, SwitzerlandArno Fritsch8Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyNeil Davie8Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyHossein-Ardeschir Ghofrani9Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center of Lung Research (DZL), Giessen, Germany
- Impact of riociguat on health-related quality of life (HRQoL) in patients with pulmonary arterial hypertension (PAH)By Hossein-Ardeschir Ghofrani, Nazzareno Galiè, Friedrich Grimminger, Marc Humbert, Anne M. Keogh, Lewis J. Rubin, Mirko Sikirica, Arno Fritsch, Neil Davie, Stacie Hudgens, Nicola Bonner, Ba Luong and David LanglebenHossein-Ardeschir Ghofrani1Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center of Lung Research (DZL), Giessen, GermanyNazzareno Galiè2Institute of Cardiology, University of Bologna, Bologna, ItalyFriedrich Grimminger1Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center of Lung Research (DZL), Giessen, GermanyMarc Humbert3Univ. Paris-Sud, Inserm U999; AP-HP, Hôpital Bicêtre, Service De Pneumologie, Le Kremlin-Bicêtre, FranceAnne M. Keogh4Heart Lung Transplant Unit, St Vincent's Hospital, Sydney, AustraliaLewis J. Rubin5School of Medicine, University of California, San Diego, La Jolla, United StatesMirko Sikirica6Global HEOR, Bayer HealthCare Pharmaceuticals, Berlin, GermanyArno Fritsch7Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyNeil Davie7Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyStacie Hudgens8Healthcare Analytics, Adelphi Values US, Boston, United StatesNicola Bonner9Patient Reported Outcomes, Adelphi Values UK, Bollington, United KingdomBa Luong6Global HEOR, Bayer HealthCare Pharmaceuticals, Berlin, GermanyDavid Langleben10Center for Pulmonary Vascular Disease, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Canada
- Impact of riociguat on health-related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)By Hossein-Ardeschir Ghofrani, Friedrich Grimminger, Marius M. Hoeper, Nick H. Kim, Eckhard Mayer, Gerald Simonneau, Mirko Sikirica, Arno Fritsch, Neil Davie, Ba Luong and Martin R. WilkinsHossein-Ardeschir Ghofrani1Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center of Lung Research (DZL), Giessen, GermanyFriedrich Grimminger1Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center of Lung Research (DZL), Giessen, GermanyMarius M. Hoeper2Clinic for Respiratory Medicine, Hannover Medical School, Hannover, GermanyNick H. Kim3Division of Pulmonary and Critical Care Medicine, UCSD School of Medicine, San Diego, United StatesEckhard Mayer4Department of Thoracic Surgery, Kerckhoff Heart and Lung Center, Bad Nauheim, GermanyGerald Simonneau5Univ. Paris-Sud, Inserm U999; AP-HP, Hôpital Bicêtre, Service De Pneumologie, Le Kremlin-Bicêtre, FranceMirko Sikirica6Global HEOR, Bayer HealthCare Pharmaceuticals, Berlin, GermanyArno Fritsch7Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyNeil Davie7Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyBa Luong6Global HEOR, Bayer HealthCare Pharmaceuticals, Berlin, GermanyMartin R. Wilkins8Centre for Pharmacology and Therapeutics, Division of Experimental Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom
- Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST-1 studyBy Andrea M. D'Armini, Hossein-Ardeschir Ghofrani, Nick H. Kim, Eckhard Mayer, Gerald Simonneau, Martin R. Wilkins, Tomás Pulido, Arno Fritsch, Neil Davie and Marius M. HoeperAndrea M. D'Armini1Division of Cardiac Surgery, IRCCS Policlinico San Matteo, University of Pavia School of Medicine, Pavia, ItalyHossein-Ardeschir Ghofrani2Department of Internal Medicine, University of Giessen and Marburg Lung Center, Member of the German Center of Lung Research (DZL), Giessen, GermanyNick H. Kim3Division of Pulmonary and Critical Care Medicine, UCSD School of Medicine, San Diego, United StatesEckhard Mayer4Department of Thoracic Surgery, Kerckhoff Heart and Lung Center, Bad Nauheim, GermanyGerald Simonneau5Univ. Paris-Sud; Inserm U999; AP-HP, Hôpital Bicêtre, Service De Pneumologie, Le Kremlin-Bicêtre, FranceMartin R. Wilkins6Centre for Pharmacology and Therapeutics, Division of Experimental Medicine, Imperial College London, Hammersmith Hospital, London, United KingdomTomás Pulido7Cardiopulmonary Department, National Heart Institute, Mexico City, MexicoArno Fritsch8Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyNeil Davie8Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyMarius M. Hoeper9Clinic for Respiratory Medicine, Hannover Medical School, Hannover, Germany
- An interim analysis of the phase III riociguat long-term extension study in CTEPH (CHEST-2)By Gerald Simonneau, Andrea M. D'Armini, Hossein-Ardeschir Ghofrani, Friedrich Grimminger, Marius M. Hoeper, Pavel Jansa, Nick H. Kim, Chen Wang, Martin R. Wilkins, Arno Fritsch, Neil Davie, Gerrit Weimann and Eckhard MayerGerald Simonneau1Univ. Paris-Sud; Inserm U999; AP-HP, Hôpital Bicêtre, Service De Pneumologie, Le Kremlin-Bicêtre, FranceAndrea M. D'Armini2Division of Cardiac Surgery, IRCCS Policlinico San Matteo, University of Pavia School of Medicine, Pavia, ItalyHossein-Ardeschir Ghofrani3Department of Internal Medicine, University of Giessen and Marburg Lung Center, Member of the German Center of Lung Research (DZL), Giessen, GermanyFriedrich Grimminger3Department of Internal Medicine, University of Giessen and Marburg Lung Center, Member of the German Center of Lung Research (DZL), Giessen, GermanyMarius M. Hoeper4Clinic for Respiratory Medicine, Hannover Medical School, Hannover, GermanyPavel Jansa5Clinical Department of Cardiology and Angiology, First Faculty of Medicine and General Teaching Hospital, Prague, Czech RepublicNick H. Kim6Division of Pulmonary and Critical Care Medicine, UCSD School of Medicine, San Diego, United StatesChen Wang7Department of Respiratory Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao Yang Hospital, Capital Medical University, Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing, ChinaMartin R. Wilkins8Centre for Pharmacology and Therapeutics, Division of Experimental Medicine, Imperial College London, Hammersmith Hospital, London, United KingdomArno Fritsch9Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyNeil Davie9Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyGerrit Weimann9Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyEckhard Mayer10Department of Thoracic Surgery, Kerckhoff Heart and Lung Center, Bad Nauheim, Germany
- Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2)By Gérald Simonneau, Andrea M. D’Armini, Hossein-Ardeschir Ghofrani, Friedrich Grimminger, Marius M. Hoeper, Pavel Jansa, Nick H. Kim, Chen Wang, Martin Wilkins, Arno Fritsch, Neil Davie, Pablo Colorado and Eckhard MayerArticle | Published in 2014 in European Respiratory JournalGérald Simonneau1Assistance Publique–Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d’Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin–Bicêtre, FranceAndrea M. D’Armini2Division of Cardiothoracic Surgery, Foundation “I.R.C.C.S. Policlinico San Matteo”, University of Pavia School of Medicine, Pavia, ItalyHossein-Ardeschir Ghofrani3University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany, and Member of the German Center of Lung Research (DZL)4Dept of Medicine, Imperial College London, London, UKFriedrich Grimminger3University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany, and Member of the German Center of Lung Research (DZL)Marius M. Hoeper5Clinic for Respiratory Medicine, Hannover Medical School, Hannover, Germany, and Member of the German Center of Lung Research (DZL)Pavel Jansa6Clinical Dept of Cardiology and Angiology, First Faculty of Medicine and General Teaching Hospital, Prague, Czech RepublicNick H. Kim7Division of Pulmonary and Critical Care Medicine, School of Medicine, University of California San Diego, San Diego, CA, USAChen Wang8Beijing Institute of Respiratory Medicine, Beijing Chao Yang Hospital, Dept of Respiratory Medicine, Capital Medical University, Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing, ChinaMartin Wilkins9National Institute for Health Research/Wellcome Trust Imperial Clinical Research Facility, Imperial Centre for Translational and Experimental Medicine, Imperial College London, London, UKArno Fritsch10Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyNeil Davie10Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyPablo Colorado11Global Clinical Development, Bayer HealthCare Pharmaceuticals, Barcelona, SpainEckhard Mayer12Kerckhoff Heart and Lung Center, Bad Nauheim, Germany
- Late-breaking abstract: Riociguat for the treatment of pulmonary arterial hypertension (PAH): 2-year results from the PATENT-2 long-term extensionBy Lewis J. Rubin, Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marc Humbert, Zhi-Cheng Jing, Anne Keogh, David Langleben, Arno Fritsch, Flavia Menezes, Neil Davie and Hossein-Ardeschir GhofraniLewis J. Rubin1School of Medicine, University of California, San Diego, La Jolla,Nazzareno Galiè2Dept of Experimental, Diagnostic and Specialty Medicine–DIMES, Bologna University Hospital, Bologna, ItalyFriedrich Grimminger3Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), member of the German Center of Lung Research (DZL), Giessen, GermanyEkkehard Grünig4Centre for Pulmonary Hypertension at the Thoraxclinic, University Hospital Heidelberg, Heidelberg, GermanyMarc Humbert5Assistance Publique–Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin–Bicêtre, FranceZhi-Cheng Jing6State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, ChinaAnne Keogh7Cardiac Transplant, St Vincent's Hospital, Sydney, AustraliaDavid Langleben8Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, CanadaArno Fritsch9Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyFlavia Menezes10Clinical Development, Bayer HealthCare Pharmaceuticals, São Paulo, BrazilNeil Davie9Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyHossein-Ardeschir Ghofrani3Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), member of the German Center of Lung Research (DZL), Giessen, Germany11Dept of Medicine, Imperial College London, London, United Kingdom
- Late-breaking abstract: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 2-year results from the CHEST-2 long-term extensionBy Gérald Simonneau, Andrea M. D'Armini, Hossein-Ardeschir Ghofrani, Friedrich Grimminger, Marius M. Hoeper, Pavel Jansa, Nick H. Kim, Chen Wang, Martin Wilkins, Arno Fritsch, Neil Davie, Pablo Colorado and Eckhard MayerGérald Simonneau1Assistance Publique–Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin–Bicêtre, FranceAndrea M. D'Armini2Division of Cardiothoracic Surgery, Foundation "I.R.C.C.S. Policlinico San Matteo", University of Pavia School of Medicine, Pavia, ItalyHossein-Ardeschir Ghofrani3Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), member of the German Center of Lung Research (DZL), Giessen, Germany4Dept of Medicine, Imperial College London, London, United KingdomFriedrich Grimminger3Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), member of the German Center of Lung Research (DZL), Giessen, GermanyMarius M. Hoeper5Clinic for Respiratory Medicine, Hannover Medical School, Member of the German Center of Lung Research (DZL), Hannover, GermanyPavel Jansa6Clinical Dept of Cardiology and Angiology, First Faculty of Medicine and General Teaching Hospital, Prague, Czech RepublicNick H. Kim7Division of Pulmonary and Critical Care Medicine, School of Medicine, University of California, San Diego, La Jolla,Chen Wang8Beijing Institute of Respiratory Medicine, Beijing Chao Yang Hospital, Dept of Respiratory Medicine, Capital Medical University, Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing, ChinaMartin Wilkins9National Institute for Health Research/Wellcome Trust Imperial Clinical Research Facility, Imperial Centre for Translational and Experimental Medicine, Imperial College London, London, United KingdomArno Fritsch10Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyNeil Davie10Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyPablo Colorado11Global Clinical Development, Bayer HealthCare Pharmaceuticals, Barcelona, SpainEckhard Mayer12Department of Thoracic Surgery, Kerckhoff Heart and Lung Center, Bad Nauheim, Germany
- Effects of riociguat in patients with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary endarterectomy (PEA)By Eckhard Mayer, Andrzej Biederman, Andrea M. D'Armini, Ekkehard Grünig, Pavel Jansa, David P. Jenkins, Nick H. Kim, Walter Klepetko, Jaroslav Lindner, Michael M. Madani, Chen Wang, Neil Davie, Arno Fritsch and Hossein-Ardeschir GhofraniEckhard Mayer1Department of Thoracic Surgery, Kerckhoff Heart and Lung Center, Bad Nauheim, GermanyAndrzej Biederman2Department of Cardiac Surgery, Alendort Hospital, Warsaw, PolandAndrea M. D'Armini3Division of Cardiothoracic Surgery, Foundation "I.R.C.C.S. Policlinico San Matteo", University of Pavia School of Medicine, Pavia, ItalyEkkehard Grünig4Centre for Pulmonary Hypertension, Thoraxclinic, University Hospital Heidelberg, Heidelberg, GermanyPavel Jansa5Clinical Department of Cardiology and Angiology, First Faculty of Medicine and General Teaching Hospital, Prague, Czech RepublicDavid P. Jenkins6National Pulmonary Endarterectomy Service, Papworth Hospital, Cambridge, United KingdomNick H. Kim7Division of Pulmonary and Critical Care Medicine, UCSD School of Medicine, San Diego, CA,Walter Klepetko8Department of Cardiothoracic Surgery, Vienna General Hospital, Medical University of Vienna, Vienna, AustriaJaroslav Lindner92nd Surgical Department – Clinical Department of Cardiovascular Surgery, Charles University Prague, First Faculty of Medicine and General Teaching Hospital, Prague, Czech RepublicMichael M. Madani10Division of Cardiovascular and Thoracic Surgery, University of California San Diego Medical Center, San Diego, CA,Chen Wang11Beijing Institute of Respiratory Medicine, Beijing Chao Yang Hospital, Department of Respiratory Medicine, Capital Medical University, Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing, ChinaNeil Davie12Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyArno Fritsch12Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyHossein-Ardeschir Ghofrani13Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center of Lung Research (DZL), Giessen, Germany
- Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)By Lewis J. Rubin, Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marc Humbert, Zhi-Cheng Jing, Anne Keogh, David Langleben, Arno Fritsch, Flavia Menezes, Neil Davie and Hossein-Ardeschir GhofraniArticle | Published in 2015 in European Respiratory JournalLewis J. Rubin1Dept of Medicine, University of California, San Diego, La Jolla, California, USANazzareno Galiè2Dept of Experimental, Diagnostic and Specialty Medicine–DIMES, Bologna University Hospital, Bologna, ItalyFriedrich Grimminger3University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany4Member of the German Center of Lung Research (DZL)Ekkehard Grünig5Centre for Pulmonary Hypertension, Thoraxclinic, University Hospital Heidelberg, Heidelberg, GermanyMarc Humbert6Université Paris-Sud, Le Kremlin-Bicêtre, France7AP-HP Service de Pneumologie, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France8INSERM U999, LabEx LERMIT, Centre Chirurgical Marie Lannelongue, Le Plessis, Robinson, FranceZhi-Cheng Jing9State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, ChinaAnne Keogh10St Vincent's Hospital, Sydney, AustraliaDavid Langleben11Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, CanadaArno Fritsch12Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyFlavia Menezes13Bayer HealthCare Pharmaceuticals, São Paulo, BrazilNeil Davie12Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyHossein-Ardeschir Ghofrani3University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany4Member of the German Center of Lung Research (DZL)14Dept of Medicine, Imperial College London, London, UK
- Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2)By Gérald Simonneau, Andrea M. D’Armini, Hossein-Ardeschir Ghofrani, Friedrich Grimminger, Marius M. Hoeper, Pavel Jansa, Nick H. Kim, Chen Wang, Martin R. Wilkins, Arno Fritsch, Neil Davie, Pablo Colorado and Eckhard MayerGérald Simonneau1Assistance Publique–Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d’Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin–Bicêtre, FranceAndrea M. D’Armini2Division of Cardiothoracic Surgery, Foundation “I.R.C.C.S. Policlinico San Matteo”, University of Pavia School of Medicine, Pavia, ItalyHossein-Ardeschir Ghofrani3University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany, and Member of the German Center of Lung Research (DZL)4Dept of Medicine, Imperial College London, London, UKFriedrich Grimminger3University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany, and Member of the German Center of Lung Research (DZL)Marius M. Hoeper5Clinic for Respiratory Medicine, Hannover Medical School, Hannover, Germany, and Member of the German Center of Lung Research (DZL)Pavel Jansa6Clinical Dept of Cardiology and Angiology, First Faculty of Medicine and General Teaching Hospital, Prague, Czech RepublicNick H. Kim7Division of Pulmonary and Critical Care Medicine, School of Medicine, University of California San Diego, San Diego, CA, USAChen Wang8Beijing Institute of Respiratory Medicine, Beijing Chao Yang Hospital, Dept of Respiratory Medicine, Capital Medical University, Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing, ChinaMartin R. Wilkins9National Institute for Health Research/Wellcome Trust Imperial Clinical Research Facility, Imperial Centre for Translational and Experimental Medicine, Imperial College London, London, UKArno Fritsch10Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyNeil Davie10Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyPablo Colorado11Global Clinical Development, Bayer HealthCare Pharmaceuticals, Barcelona, SpainEckhard Mayer12Kerckhoff Heart and Lung Center, Bad Nauheim, Germany
- Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)By Lewis J. Rubin, Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marc Humbert, Zhi-Cheng Jing, Anne Keogh, David Langleben, Arno Fritsch, Flavia Menezes, Neil Davie and Hossein-Ardeschir GhofraniLewis J. Rubin1Dept of Medicine, University of California, San Diego, La Jolla, California, USANazzareno Galiè2Dept of Experimental, Diagnostic and Specialty Medicine–DIMES, Bologna University Hospital, Bologna, ItalyFriedrich Grimminger3University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany4Member of the German Center of Lung Research (DZL)Ekkehard Grünig5Centre for Pulmonary Hypertension, Thoraxclinic, University Hospital Heidelberg, Heidelberg, GermanyMarc Humbert6Université Paris-Sud, Le Kremlin-Bicêtre, France7AP-HP Service de Pneumologie, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France8INSERM U999, LabEx LERMIT, Centre Chirurgical Marie Lannelongue, Le Plessis, Robinson, FranceZhi-Cheng Jing9State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, ChinaAnne Keogh10St Vincent's Hospital, Sydney, AustraliaDavid Langleben11Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, CanadaArno Fritsch12Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyFlavia Menezes13Bayer HealthCare Pharmaceuticals, São Paulo, BrazilNeil Davie12Global Clinical Development, Bayer HealthCare Pharmaceuticals, Wuppertal, GermanyHossein-Ardeschir Ghofrani3University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany4Member of the German Center of Lung Research (DZL)14Dept of Medicine, Imperial College London, London, UK
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.